1-7 of 7
Allison J Berger, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim
Journal: Blood
Blood (2019) 134 (Supplement_1): 1593.
https://doi.org/10.1182/blood-2019-128773
Published: 2019
Journal Articles

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Scott R Best, BS, Vi Lam, Nur Bruss, BS, Taylor Hashiguchi Rowland, BS, Adam S. Kittai, MD, Tingting Liu, Allison J Berger, PhD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4313.
https://doi.org/10.1182/blood-2019-123600
Published: 2019
Journal Articles

Targeting Nedd8 Activating Enzyme Induces DNA Damage and Cell Cycle Arrest and Sensitizes Chronic Lymphocytic Leukemia (CLL) B-Cells to Alkylating Agents

Claire Godbersen, Cody Paiva, Allison J Berger, PhD, Jennifer R. Brown, MD, Alexey V. Danilov, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4690.
https://doi.org/10.1182/blood.V124.21.4690.4690
Published: 2014
Journal Articles

Preclinical Combination Of The Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit In Multiple Myeloma Cell Lines and Xenograft Models

Allison J Berger, PhD, Bret Bannerman, Steven N Quayle, PhD, Jie Yu, Khristofer Garcia, Jeffrey Ciavarri, PhD, David Tamang, PhD, Min Yang, PhD, Simon S Jones, PhD
Journal: Blood
Blood (2013) 122 (21): 4437.
https://doi.org/10.1182/blood.V122.21.4437.4437
Published: 2013
Journal Articles

Preclinical Efficacy of the Investigational Orally Bioavailable Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Antonio Garcia-Gomez, Dalia Quwaider, Enrique M Ocio, MD, PhD, Laura San-Segundo, Teresa Paíno, Juan F Blanco, Allison J Berger, PhD, Atanasio Pandiella, MD, PhD, Jesús F San-Miguel, MD, PhD, Mercedes Garayoa
Journal: Blood
Blood (2012) 120 (21): 4014.
https://doi.org/10.1182/blood.V120.21.4014.4014
Published: 2012
Journal Articles

MLN4924, a Potent and Novel Small Molecule Inhibitor of Nedd8 Activating Enzyme, Induces DNA Re-Replication and Apoptosis in Cultured Human Tumor Cells

Michael Milhollen, MSc, Usha Narayanan, Jennifer Duffy, Ben Amidon, Teresa A Soucy, PhD, Allison J Berger, PhD, Steven P. Langston, Todd Sells, Peter G Smith, PhD
Journal: Blood
Blood (2008) 112 (11): 3621.
https://doi.org/10.1182/blood.V112.11.3621.3621
Published: 2008
Journal Articles

MLN4924, a Novel Small Molecule Inhibitor of Nedd8-Activating Enzyme, Demonstrates Potent Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma

Michael Milhollen, MSc, Usha Narayanan, Allison J Berger, PhD, Michael Thomas, Tary Traore, Jie Yu, Julie Zhang, Erik Koenig, James J. Garnsey, Steven P. Langston, Teresa A Soucy, PhD, Peter G Smith, PhD
Journal: Blood
Blood (2008) 112 (11): 606.
https://doi.org/10.1182/blood.V112.11.606.606
Published: 2008